Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program

Jul 16 2016

• By Derrick Gingery

PDUFA VI letter

Related Content

PDUFA Negotiations: Early Communications, Breakthrough Still On Docket

Feb 18 2016

PDUFA V Reviews Are ‘Best Ever’ For Some Sponsors, Maybe Not FDA

Apr 06 2015

FDA Meets ANDA Backlog Goal Early, Still Doesn't Feel Out Of Woods

Jul 12 2016

Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model

Oct 01 2012

Breakthrough Requests: FDA Adds Quick Screen To Pare Workload

Nov 13 2015

PDUFA Negotiations End, Approval Process Ongoing

Feb 26 2016

FDA Review “Program” Tweaks May Include Smaller Mid-Cycle Meetings

Jul 21 2014

Two Out Of Three Ain't Bad: Biosimilar User Fee Talks Completed

Jun 20 2016

FDA's Breakthrough Bar May Be Set Too Low, Jenkins Says

Jun 30 2016

Additional Topics

United States Regulation Review Pathway Drug Review Drug Approval Standards BioPharmaceutical

More from Review Pathways

More from Pathways & Standards

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window